Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$12.66
-0.1%
$10.34
$8.02
$18.80
$6.29B1.495.07 million shs4.74 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$29.49
-2.3%
$28.96
$19.45
$53.27
$1.92B2.18562,279 shs352,793 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$10.87
-0.6%
$10.53
$8.73
$13.06
$7.76B1.235.58 million shs2.44 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$39.77
+2.5%
$37.55
$29.17
$62.40
$7.23B1.111.49 million shs1.40 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.13%-2.10%+37.64%+14.95%-25.20%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-2.25%-2.51%-3.94%-19.89%-17.39%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.64%+0.74%+1.21%+1.78%-3.72%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+2.50%+0.58%+6.08%-3.80%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.2289 of 5 stars
3.22.00.00.33.63.30.0
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.7431 of 5 stars
4.42.00.00.02.91.70.0
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
1.9092 of 5 stars
3.51.00.00.02.92.50.0
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.3481 of 5 stars
4.51.00.04.73.42.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.1719.77% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.82
Moderate Buy$55.2587.35% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5060.99% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$67.0868.68% Upside

Current Analyst Ratings Breakdown

Latest KYMR, ROIV, RVMD, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/14/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/13/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$72.00 ➝ $70.00
5/12/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $44.00
5/12/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$87.00 ➝ $80.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.42$2.62 per share4.84$12.63 per share1.00
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$58.89M32.61N/AN/A$7.12 per share4.14
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$122.59M63.27N/AN/A$7.76 per share1.40
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$742K9,983.66N/AN/A$11.09 per share3.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7431.6614.232.504.60%6.78%3.03%N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$146.96M-$3.10N/AN/AN/A-191.26%-24.96%-20.27%8/6/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)

Latest KYMR, ROIV, RVMD, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16N/AN/AN/A$62.17 millionN/A
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
2/27/2025Q4 2024
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.76-$0.88-$0.12-$0.88$14.81 million$7.39 million
2/26/2025Q4 2024
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A
2/25/2025Q4 2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.15$0.14-$0.01-$0.02$1.01 billion$1.02 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.55
8.55
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
37.91
37.91
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
14.24
14.24

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.52 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860713.55 million657.18 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million154.76 millionOptionable

Recent News About These Companies

Revolution Medicines Inc.
Research Analysts Set Expectations for RVMD Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$12.66 -0.01 (-0.06%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$12.50 -0.17 (-1.33%)
As of 05/23/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$29.49 -0.68 (-2.25%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$29.10 -0.39 (-1.32%)
As of 05/23/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$10.87 -0.07 (-0.64%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$10.97 +0.10 (+0.92%)
As of 05/23/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$39.77 +0.97 (+2.50%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$39.98 +0.20 (+0.52%)
As of 05/23/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.